Jaro Ankerst
21 – 30 of 95
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
After 6 years with Xolair; a 3-year withdrawal follow-up
(
- Contribution to journal › Article
-
Mark
Xolair Is Effective in Allergics with a Low Serum IgE Level.
(
- Contribution to journal › Article
- 2009
-
Mark
The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair (R)) treatment
(
- Contribution to journal › Article
- 2008
-
Mark
Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.
(
- Contribution to journal › Article
-
Mark
Allergic rhinitis with hyper-responsiveness differ from asthma in degree of peripheral obstruction during metacholine challenge test.
(
- Contribution to journal › Article
-
Mark
Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalers
(
- Contribution to journal › Article
- 2007
-
Mark
Peripheral nitric oxide is increased in rhinitic patients with asthma compared to bronchial hyperresponsiveness.
(
- Contribution to journal › Article
-
Mark
CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment
(
- Contribution to journal › Article
- 2006
-
Mark
Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation
(
- Contribution to journal › Article